

Chi V Dang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4325858/publications.pdf>

Version: 2024-02-01

216
papers

51,046
citations

3721

89
h-index

1895

208
g-index

223
all docs

223
docs citations

223
times ranked

56407
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting cancer metabolism in the era of precision oncology. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 141-162.	21.5	385
2	Epigenetic state determines inflammatory sensing in neuroblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	21
3	Bcl-xL Enforces a Slow-Cycling State Necessary for Survival in the Nutrient-Deprived Microenvironment of Pancreatic Cancer. <i>Cancer Research</i> , 2022, 82, 1890-1908.	0.4	6
4	Peer Review: Value Added and Civility. <i>Cancer Research</i> , 2022, 82, 1157-1158.	0.4	1
5	Tilting MYC toward cancer cell death. <i>Trends in Cancer</i> , 2021, 7, 982-994.	3.8	12
6	Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. <i>Cancer Research</i> , 2021, 81, 1627-1632.	0.4	25
7	Measuring MYC-Mediated Metabolism in Tumorigenesis. <i>Methods in Molecular Biology</i> , 2021, 2318, 231-239.	0.4	5
8	Sex, life, and death in MYC-driven lymphomagenesis. <i>Molecular Cell</i> , 2021, 81, 3886-3887.	4.5	2
9	<i>Cancer Research</i> Celebrates the 50th Anniversary of the National Cancer Act and a Future of Hope. <i>Cancer Research</i> , 2021, 81, 5781-5782.	0.4	2
10	Glutamine Skipping the Q into Mitochondria. <i>Trends in Molecular Medicine</i> , 2020, 26, 6-7.	3.5	9
11	Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10984-11011.	2.9	30
12	Dynamic Imaging of LDH Inhibition in Tumors Reveals Rapid In Vivo Metabolic Rewiring and Vulnerability to Combination Therapy. <i>Cell Reports</i> , 2020, 30, 1798-1810.e4.	2.9	73
13	The MYC Oncogene Cooperates with Sterol-Regulated Element-Binding Protein to Regulate Lipogenesis Essential for Neoplastic Growth. <i>Cell Metabolism</i> , 2019, 30, 556-572.e5.	7.2	120
14	De novo synthesis of serine and glycine fuels purine nucleotide biosynthesis in human lung cancer tissues. <i>Journal of Biological Chemistry</i> , 2019, 294, 13464-13477.	1.6	58
15	Essentiality of non-essential amino acids for tumour cells and tumorigenesis. <i>Nature Metabolism</i> , 2019, 1, 847-848.	5.1	1
16	Autophagy: clocking in for the night shift. <i>EMBO Journal</i> , 2019, 38, .	3.5	4
17	mTOR Senses Intracellular pH through Lysosome Dispersion from RHEB. <i>BioEssays</i> , 2019, 41, e1800265.	1.2	9
18	Myc Regulation of a Mitochondrial Trafficking Network Mediates Tumor Cell Invasion and Metastasis. <i>Molecular and Cellular Biology</i> , 2019, 39, .	1.1	31

#	ARTICLE	IF	CITATIONS
19	Myc-mediated transcriptional regulation of the mitochondrial chaperone TRAP1 controls primary and metastatic tumor growth. <i>Journal of Biological Chemistry</i> , 2019, 294, 10407-10414.	1.6	25
20	Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. <i>Leukemia</i> , 2019, 33, 2429-2441.	3.3	24
21	Misregulation of Drosophila Myc Disrupts Circadian Behavior and Metabolism. <i>Cell Reports</i> , 2019, 29, 1778-1788.e4.	2.9	5
22	The role of long noncoding RNAs in cancer: the dark matter matters. <i>Current Opinion in Genetics and Development</i> , 2018, 48, 8-15.	1.5	122
23	MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. <i>Cancer Research</i> , 2018, 78, 64-74.	0.4	87
24	A PERK-miR-211 axis suppresses circadian regulators and protein synthesis to promote cancer cell survival. <i>Nature Cell Biology</i> , 2018, 20, 104-115.	4.6	86
25	Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy. <i>Trends in Cell Biology</i> , 2018, 28, 201-212.	3.6	94
26	Shedding Light on the Dark Cancer Genomes: Long Noncoding RNAs as Novel Biomarkers and Potential Therapeutic Targets for Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1816-1823.	1.9	30
27	MYC-induced metabolic stress and tumorigenesis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1870, 43-50.	3.3	30
28	Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR. <i>Cell</i> , 2018, 174, 72-87.e32.	13.5	172
29	IRE1 \pm RNase α -dependent lipid homeostasis promotes survival in Myc-transformed cancers. <i>Journal of Clinical Investigation</i> , 2018, 128, 1300-1316.	3.9	96
30	Correspondence: Oncogenic MYC persistently upregulates the molecular clock component REV-ERB β . <i>Nature Communications</i> , 2017, 8, 14862.	5.8	17
31	c-MYC mRNA tail tale about glutamine control of transcription. <i>EMBO Journal</i> , 2017, 36, 1806-1808.	3.5	4
32	Drugging the 'undruggable' cancer targets. <i>Nature Reviews Cancer</i> , 2017, 17, 502-508.	12.8	620
33	Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin. <i>Clinical Cancer Research</i> , 2017, 23, 5639-5647.	3.2	76
34	Clock Regulation of Metabolites Reveals Coupling between Transcription and Metabolism. <i>Cell Metabolism</i> , 2017, 25, 961-974.e4.	7.2	162
35	Pancreatic Cancer: A Riddle Wrapped in a Mystery inside an Enigma. <i>Clinical Cancer Research</i> , 2017, 23, 1629-1637.	3.2	38
36	Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	180

#	ARTICLE	IF	CITATIONS
37	Feeding frenzy for cancer cells. <i>Science</i> , 2017, 358, 862-863.	6.0	8
38	Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH). <i>Journal of Medicinal Chemistry</i> , 2017, 60, 9184-9204.	2.9	98
39	MUC-king with HIF May Rewire Pyrimidine Biosynthesis and Curb Gemcitabine Resistance in Pancreatic Cancer. <i>Cancer Cell</i> , 2017, 32, 3-5.	7.7	7
40	BETting on combination to overcome PARPi resistance. <i>Oncotarget</i> , 2017, 8, 84630-84631.	0.8	1
41	EGF induces epithelial-mesenchymal transition and cancer stem-like cell properties in human oral cancer cells via promoting Warburg effect. <i>Oncotarget</i> , 2017, 8, 9557-9571.	0.8	82
42	Warburg Effect. , 2017, , 4845-4849.		0
43	A Time for MYC: Metabolism and Therapy. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2016, 81, 79-83.	2.0	49
44	Long noncoding RNA LINP1 regulates repair of DNA double-strand breaks in triple-negative breast cancer. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 522-530.	3.6	231
45	From Krebs to clinic: glutamine metabolism to cancer therapy. <i>Nature Reviews Cancer</i> , 2016, 16, 619-634.	12.8	1,367
46	MYC, Metabolic Synthetic Lethality, and Cancer. <i>Recent Results in Cancer Research</i> , 2016, 207, 73-91.	1.8	31
47	Hepatocellular carcinoma redirects to ketolysis for progression under nutrition deprivation stress. <i>Cell Research</i> , 2016, 26, 1112-1130.	5.7	112
48	Turning publicly available gene expression data into discoveries using gene set context analysis. <i>Nucleic Acids Research</i> , 2016, 44, e8-e8.	6.5	11
49	The Ketogenic Diet Does Not Affect Growth of Hedgehog Pathway Medulloblastoma in Mice. <i>PLoS ONE</i> , 2015, 10, e0133633.	1.1	30
50	Web of the Extended Myc Network Captures Metabolism for Tumorigenesis. <i>Cancer Cell</i> , 2015, 27, 160-162.	7.7	14
51	Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function. <i>Cancer Research</i> , 2015, 75, 3355-3364.	0.4	129
52	MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 6539-6544.	3.3	211
53	Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate. <i>Clinical Cancer Research</i> , 2015, 21, 3263-3273.	3.2	129
54	A metabolic perspective of Peto's paradox and cancer. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20140223.	1.8	27

#	ARTICLE	IF	CITATIONS
55	An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis. <i>Cancer Cell</i> , 2015, 28, 472-485.	7.7	74
56	Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. <i>Cancer Cell</i> , 2015, 28, 529-540.	7.7	601
57	Splicing and Dicing MYC-Mediated Synthetic Lethality. <i>Cancer Cell</i> , 2015, 28, 405-406.	7.7	10
58	MYC and metabolism on the path to cancer. <i>Seminars in Cell and Developmental Biology</i> , 2015, 43, 11-21.	2.3	253
59	MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells. <i>Cell Metabolism</i> , 2015, 22, 1009-1019.	7.2	217
60	MYC, Metabolism, and Cancer. <i>Cancer Discovery</i> , 2015, 5, 1024-1039.	7.7	919
61	MYC Regulation of Metabolism and Cancer. , 2015, , 101-122.		1
62	Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. <i>Journal of Clinical Investigation</i> , 2015, 125, 2293-2306.	3.9	319
63	Q-ing tumor glutaminase therapy. <i>Oncotarget</i> , 2015, 6, 38440-38441.	0.8	3
64	Tumorigenicity of hypoxic respiring cancer cells revealed by a hypoxia- cell cycle dual reporter. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 12486-12491.	3.3	48
65	Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. <i>Experimental Hematology</i> , 2014, 42, 247-251.	0.2	125
66	Blocking Lactate Export by Inhibiting the Myc Target MCT1 Disables Glycolysis and Glutathione Synthesis. <i>Cancer Research</i> , 2014, 74, 908-920.	0.4	291
67	Fine-tuned amplification in cells. <i>Nature</i> , 2014, 511, 417-418.	13.7	26
68	Isotopically nonstationary ¹³ C flux analysis of Myc-induced metabolic reprogramming in B-cells. <i>Metabolic Engineering</i> , 2013, 15, 206-217.	3.6	81
69	Stress eating and tuning out: Cancer cells re-wire metabolism to counter stress. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2013, 48, 609-619.	2.3	32
70	MYC, Metabolism, Cell Growth, and Tumorigenesis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2013, 3, a014217-a014217.	2.9	494
71	MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients. <i>Blood Cells, Molecules, and Diseases</i> , 2013, 50, 190-195.	0.6	21
72	Role of aerobic glycolysis in genetically engineered mouse models of cancer. <i>BMC Biology</i> , 2013, 11, 3.	1.7	12

#	ARTICLE	IF	CITATIONS
73	A Nontranscriptional Role for HIF-1 α as a Direct Inhibitor of DNA Replication. <i>Science Signaling</i> , 2013, 6, ra10.	1.6	95
74	Evaluation of LDH-A and Glutaminase Inhibition <i>In Vivo</i> by Hyperpolarized ¹³ C-Pyruvate Magnetic Resonance Spectroscopy of Tumors. <i>Cancer Research</i> , 2013, 73, 4190-4195.	0.4	61
75	ChIP-PED enhances the analysis of ChIP-seq and ChIP-chip data. <i>Bioinformatics</i> , 2013, 29, 1182-1189.	1.8	12
76	Studying Myc's Role in Metabolism Regulation. <i>Methods in Molecular Biology</i> , 2013, 1012, 213-219.	0.4	24
77	Conceptual Framework for Cutting the Pancreatic Cancer Fuel Supply. <i>Clinical Cancer Research</i> , 2012, 18, 4285-4290.	3.2	52
78	Cancer Cell Metabolism: There Is No ROS for the Weary. <i>Cancer Discovery</i> , 2012, 2, 304-307.	7.7	22
79	Old and fat, oncogenes make you. <i>Cell Cycle</i> , 2012, 11, 1272-1272.	1.3	0
80	Design, Synthesis, and Pharmacological Evaluation of Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl Sulfide 3 (BPTES) Analogs as Glutaminase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10551-10563.	2.9	163
81	MYC on the Path to Cancer. <i>Cell</i> , 2012, 149, 22-35.	13.5	2,577
82	Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells. <i>Cell Metabolism</i> , 2012, 15, 110-121.	7.2	923
83	Links between metabolism and cancer. <i>Genes and Development</i> , 2012, 26, 877-890.	2.7	846
84	Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 8983-8988.	3.3	399
85	Normal and cancer cell metabolism: lymphocytes and lymphoma. <i>FEBS Journal</i> , 2012, 279, 2598-2609.	2.2	53
86	Array-Based Nuclear Run-On Analysis. <i>Methods in Molecular Biology</i> , 2012, 809, 505-517.	0.4	7
87	Alterations in Nucleolar Structure and Gene Expression Programs in Prostatic Neoplasia Are Driven by the MYC Oncogene. <i>American Journal of Pathology</i> , 2011, 178, 1824-1834.	1.9	113
88	Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1. <i>Cell</i> , 2011, 146, 772-784.	13.5	1,304
89	Cell-Type Independent MYC Target Genes Reveal a Primordial Signature Involved in Biomass Accumulation. <i>PLoS ONE</i> , 2011, 6, e26057.	1.1	147
90	Otto Warburg's contributions to current concepts of cancer metabolism. <i>Nature Reviews Cancer</i> , 2011, 11, 325-337.	12.8	2,566

#	ARTICLE	IF	CITATIONS
91	Metabolic and electrochemical mechanisms of dimeric naphthoquinones cytotoxicity in breast cancer cells. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 7057-7062.	1.4	12
92	Therapeutic targeting of cancer cell metabolism. <i>Journal of Molecular Medicine</i> , 2011, 89, 205-212.	1.7	151
93	Warburg Effect. , 2011, , 3941-3945.		0
94	Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation. <i>Cancer Cell</i> , 2010, 18, 207-219.	7.7	707
95	Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation. <i>Cancer Cell</i> , 2010, 18, 397.	7.7	9
96	Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy. <i>Nature Genetics</i> , 2010, 42, 840-850.	9.4	295
97	p32 (C1QBP) and Cancer Cell Metabolism: Is the Warburg Effect a Lot of Hot Air?. <i>Molecular and Cellular Biology</i> , 2010, 30, 1300-1302.	1.1	37
98	MYC and Prostate Cancer. <i>Genes and Cancer</i> , 2010, 1, 617-628.	0.6	245
99	Rethinking the Warburg Effect with Myc Micromanaging Glutamine Metabolism. <i>Cancer Research</i> , 2010, 70, 859-862.	0.4	353
100	Glutaminolysis: Supplying carbon or nitrogen or both for cancer cells?. <i>Cell Cycle</i> , 2010, 9, 3884-3886.	1.3	209
101	Enigmatic MYC Conducts an Unfolding Systems Biology Symphony. <i>Genes and Cancer</i> , 2010, 1, 526-531.	0.6	56
102	Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 3534-3539.	3.3	47
103	Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1. <i>Cancer Research</i> , 2010, 70, 8981-8987.	0.4	439
104	Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 2037-2042.	3.3	1,150
105	MYC Overexpression Induces Prostatic Intraepithelial Neoplasia and Loss of Nkx3.1 in Mouse Luminal Epithelial Cells. <i>PLoS ONE</i> , 2010, 5, e9427.	1.1	113
106	Time-Dependent c-Myc Transactomes Mapped by Array-Based Nuclear Run-On Reveal Transcriptional Modules in Human B Cells. <i>PLoS ONE</i> , 2010, 5, e9691.	1.1	37
107	Myc and Control of Tumor Neovascularization. , 2010, , 167-187.		1
108	Differential Regulation of MicroRNA Expression In Polycythemia Vera CD34+ Cells. <i>Blood</i> , 2010, 116, 4785-4785.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3384-3389.	3.3	355
110	MYC, microRNAs and glutamine addiction in cancers. Cell Cycle, 2009, 8, 3243-3245.	1.3	68
111	MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities. Clinical Cancer Research, 2009, 15, 6479-6483.	3.2	738
112	PKM2 Tyrosine Phosphorylation and Glutamine Metabolism Signal a Different View of the Warburg Effect. Science Signaling, 2009, 2, pe75.	1.6	60
113	Edging toward New Therapeutics with Cyclin D1 Egl'ng on Cancer. Cancer Cell, 2009, 16, 361-362.	7.7	0
114	Micro-managing and restraining pluripotent stem cells by MYC. EMBO Journal, 2009, 28, 3065-3066.	3.5	6
115	c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature, 2009, 458, 762-765.	13.7	1,801
116	Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood, 2009, 114, 5473-5480.	0.6	364
117	Myoglobin tames tumor growth and spread. Journal of Clinical Investigation, 2009, 119, 766-768.	3.9	4
118	Widespread microRNA repression by Myc contributes to tumorigenesis. Nature Genetics, 2008, 40, 43-50.	9.4	1,203
119	The interplay between MYC and HIF in cancer. Nature Reviews Cancer, 2008, 8, 51-56.	12.8	535
120	Muscle Fatigue from Losing Your PHD. Cell Metabolism, 2008, 7, 191-192.	7.2	1
121	Digoxin and other cardiac glycosides inhibit HIF-1 α synthesis and block tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19579-19586.	3.3	568
122	Antimalarial therapy prevents Myc-induced lymphoma. Journal of Clinical Investigation, 2008, 118, 15-17.	3.9	24
123	Global Regulation of Nucleotide Biosynthetic Genes by c-Myc. PLoS ONE, 2008, 3, e2722.	1.1	239
124	Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins. Journal of the American Association for Laboratory Animal Science, 2008, 47, 37-40.	0.6	89
125	The c-Myc Target Gene Rcl (C6orf108) Encodes a Novel Enzyme, Deoxynucleoside 5 α -monophosphate N-Glycosidase. Journal of Biological Chemistry, 2007, 282, 8150-8156.	1.6	36
126	Hypoxia-Inducible Factor 1 and Dysregulated c-Myc Cooperatively Induce Vascular Endothelial Growth Factor and Metabolic Switches Hexokinase 2 and Pyruvate Dehydrogenase Kinase 1. Molecular and Cellular Biology, 2007, 27, 7381-7393.	1.1	540

#	ARTICLE	IF	CITATIONS
127	Biology and treatment of Burkitt's lymphoma. <i>Current Opinion in Hematology</i> , 2007, 14, 375-381.	1.2	74
128	HIF-1 Regulates Cytochrome Oxidase Subunits to Optimize Efficiency of Respiration in Hypoxic Cells. <i>Cell</i> , 2007, 129, 111-122.	13.5	1,068
129	Discovering robust protein biomarkers for disease from relative expression reversals in 2-D DIGE data.. <i>Proteomics</i> , 2007, 7, 1197-1207.	1.3	21
130	HIF-1 Inhibits Mitochondrial Biogenesis and Cellular Respiration in VHL-Deficient Renal Cell Carcinoma by Repression of C-MYC Activity. <i>Cancer Cell</i> , 2007, 11, 407-420.	7.7	760
131	HIF-Dependent Antitumorigenic Effect of Antioxidants In Vivo. <i>Cancer Cell</i> , 2007, 12, 230-238.	7.7	466
132	Isolation of Bone Marrow-Derived Stem Cells using Density-Gradient Separation. <i>Experimental Hematology</i> , 2007, 35, 335-341.	0.2	47
133	Effects of hypoxia on tumor metabolism. <i>Cancer and Metastasis Reviews</i> , 2007, 26, 291-298.	2.7	123
134	HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. <i>Cell Metabolism</i> , 2006, 3, 177-185.	7.2	3,112
135	Cancer's Molecular Sweet Tooth and the Warburg Effect: Figure 1.. <i>Cancer Research</i> , 2006, 66, 8927-8930.	0.4	1,086
136	The c-Myc target gene network. <i>Seminars in Cancer Biology</i> , 2006, 16, 253-264.	4.3	989
137	Conditional Deletion of c-myc Does Not Impair Liver Regeneration. <i>Cancer Research</i> , 2006, 66, 5608-5612.	0.4	40
138	Activation of Transferrin Receptor 1 by c-Myc Enhances Cellular Proliferation and Tumorigenesis. <i>Molecular and Cellular Biology</i> , 2006, 26, 2373-2386.	1.1	210
139	Global mapping of c-Myc binding sites and target gene networks in human B cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 17834-17839.	3.3	462
140	c-Myc Overexpression Causes Anaplasia in Medulloblastoma. <i>Cancer Research</i> , 2006, 66, 673-681.	0.4	111
141	Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. <i>Current Opinion in Hematology</i> , 2005, 12, 1-6.	1.2	74
142	Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. <i>Blood</i> , 2005, 106, 304-310.	0.6	74
143	c-Myc-regulated microRNAs modulate E2F1 expression. <i>Nature</i> , 2005, 435, 839-843.	13.7	2,618
144	The great MYC escape in tumorigenesis. <i>Cancer Cell</i> , 2005, 8, 177-178.	7.7	99

#	ARTICLE	IF	CITATIONS
145	Multifaceted roles of glycolytic enzymes. <i>Trends in Biochemical Sciences</i> , 2005, 30, 142-150.	3.7	570
146	Stimulation of Myc transactivation by the TATA binding protein in promoter-reporter assays. <i>BMC Biochemistry</i> , 2005, 6, 7.	4.4	11
147	The Myc Target Gene JPO1/CDCA7 Is Frequently Overexpressed in Human Tumors and Has Limited Transforming Activity In vivo. <i>Cancer Research</i> , 2005, 65, 5620-5627.	0.4	53
148	Myc Stimulates Nuclearly Encoded Mitochondrial Genes and Mitochondrial Biogenesis. <i>Molecular and Cellular Biology</i> , 2005, 25, 6225-6234.	1.1	527
149	Could MYC Induction of Mitochondrial Biogenesis be linked to ROS Production and Genomic Instability?. <i>Cell Cycle</i> , 2005, 4, 1465-1466.	1.3	57
150	Oncogenic alterations of metabolism and the Warburg effect. <i>Drug Discovery Today Disease Mechanisms</i> , 2005, 2, 233-238.	0.8	20
151	In silico identification of transcriptional regulators associated with c-Myc. <i>Nucleic Acids Research</i> , 2004, 32, 4955-4961.	6.5	26
152	Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 4578-4583.	3.3	207
153	Histopathological and Molecular Prognostic Markers in Medulloblastoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004, 63, 441-449.	0.9	203
154	Evaluation of Myc E-Box Phylogenetic Footprints in Glycolytic Genes by Chromatin Immunoprecipitation Assays. <i>Molecular and Cellular Biology</i> , 2004, 24, 5923-5936.	1.1	312
155	hTERT Gene Amplification and Increased mRNA Expression in Central Nervous System Embryonal Tumors. <i>American Journal of Pathology</i> , 2003, 162, 1763-1769.	1.9	66
156	Identification and characterization of the novel centrosome-associated protein CCCAP. <i>Gene</i> , 2003, 303, 35-46.	1.0	27
157	An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. <i>Genome Biology</i> , 2003, 4, R69.	13.9	433
158	Development of Human Protein Reference Database as an Initial Platform for Approaching Systems Biology in Humans. <i>Genome Research</i> , 2003, 13, 2363-2371.	2.4	954
159	Unique conformation of cancer autoantigen B23 in hepatoma: A mechanism for specificity in the autoimmune response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 12361-12366.	3.3	63
160	Anoxic Fibroblasts Activate a Replication Checkpoint That Is Bypassed By E1a. <i>Molecular and Cellular Biology</i> , 2003, 23, 9032-9045.	1.1	21
161	Increased Expression of TATA-Binding Protein, the Central Transcription Factor, Can Contribute to Oncogenesis. <i>Molecular and Cellular Biology</i> , 2003, 23, 3043-3051.	1.1	62
162	A strategy for identifying transcription factor binding sites reveals two classes of genomic c-Myc target sites. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 5313-5318.	3.3	99

#	ARTICLE	IF	CITATIONS
163	Celebrating the physician-scientist. <i>Journal of Clinical Investigation</i> , 2003, 112, S1-2.	3.9	2
164	The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 6649-6654.	3.3	179
165	c-myc Protooncogene. , 2002, , 555-561.		10
166	Evidence for involvement of calpain in c-Myc proteolysis in vivo. <i>Archives of Biochemistry and Biophysics</i> , 2002, 400, 151-161.	1.4	32
167	Characterization of Nucleophosmin (B23) as a Myc Target by Scanning Chromatin Immunoprecipitation. <i>Journal of Biological Chemistry</i> , 2001, 276, 48285-48291.	1.6	108
168	A Novel c-Myc- responsive Gene, JPO1, Participates in Neoplastic Transformation. <i>Journal of Biological Chemistry</i> , 2001, 276, 48276-48284.	1.6	51
169	A Strategy to Identify Differentially Expressed Genes Using Representational Difference Analysis and cDNA Arrays. <i>Analytical Biochemistry</i> , 2001, 288, 141-148.	1.1	20
170	Translocations involving c-myc and c-myc function. <i>Oncogene</i> , 2001, 20, 5595-5610.	2.6	440
171	c-myc box II mutations in Burkitt's lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli. <i>Oncogene</i> , 2001, 20, 6084-6094.	2.6	19
172	Hypoxia Inhibits G1/S Transition through Regulation of p27 Expression. <i>Journal of Biological Chemistry</i> , 2001, 276, 7919-7926.	1.6	322
173	Arsenic inhibition of telomerase transcription leads to genetic instability. <i>Journal of Clinical Investigation</i> , 2001, 108, 1541-1547.	3.9	101
174	Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc. <i>Journal of Biological Chemistry</i> , 2000, 275, 21797-21800.	1.6	708
175	c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism. <i>Molecular and Cellular Biology</i> , 1999, 19, 1-11.	1.1	1,501
176	Cancer genetics: Tumor suppressor meets oncogene. <i>Current Biology</i> , 1999, 9, R62-R65.	1.8	31
177	Oncogenic alterations of metabolism. <i>Trends in Biochemical Sciences</i> , 1999, 24, 68-72.	3.7	989
178	Function of the c-Myc Oncogenic Transcription Factor. <i>Experimental Cell Research</i> , 1999, 253, 63-77.	1.2	332
179	c-Myc Overexpression Uncouples DNA Replication from Mitosis. <i>Molecular and Cellular Biology</i> , 1999, 19, 5339-5351.	1.1	119
180	Neoplastic Transformation of RK3E by Mutant β -Catenin Requires Deregulation of Tcf/Lef Transcription but Not Activation of c-myc Expression. <i>Molecular and Cellular Biology</i> , 1999, 19, 5696-5706.	1.1	287

#	ARTICLE	IF	CITATIONS
181	Elevated Extracellular Calcium Can Prevent Apoptosis via the Calcium-Sensing Receptor. <i>Biochemical and Biophysical Research Communications</i> , 1998, 249, 325-331.	1.0	96
182	Identification of a large Myc-binding protein that contains RCC1-like repeats. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 9172-9177.	3.3	125
183	Pancytopenia Secondary to Oxalosis in a 23-Year-Old Woman. <i>Blood</i> , 1998, 91, 4394-4394.	0.6	5
184	17 β -Estradiol Inhibits Apoptosis of Endothelial Cells. <i>Biochemical and Biophysical Research Communications</i> , 1997, 237, 372-381.	1.0	120
185	Mammalian BUB1 Protein Kinases: Map Positions and <i>in Vivo</i> Expression. <i>Genomics</i> , 1997, 46, 379-388.	1.3	38
186	Role of Oncogenic Transcription Factor c-Myc in Cell Cycle Regulation, Apoptosis and Metabolism. <i>Journal of Biomedical Science</i> , 1997, 4, 269-278.	2.6	1
187	Oncogenes in tumor metabolism, tumorigenesis, and apoptosis. <i>Journal of Bioenergetics and Biomembranes</i> , 1997, 29, 345-354.	1.0	105
188	Role of oncogenic transcription factor c-Myc in cell cycle regulation, apoptosis and metabolism. <i>Journal of Biomedical Science</i> , 1997, 4, 269-278.	2.6	31
189	Genomic Organization of Human MXI1, a Putative Tumor Suppressor Gene. <i>Genomics</i> , 1996, 32, 466-470.	1.3	31
190	Human T-cell Leukemia Virus Type I Tax Masks c-Myc Function through a cAMP-dependent Pathway. <i>Journal of Biological Chemistry</i> , 1996, 271, 9730-9738.	1.6	29
191	c-Myc Is Glycosylated at Threonine 58, a Known Phosphorylation Site and a Mutational Hot Spot in Lymphomas. <i>Journal of Biological Chemistry</i> , 1995, 270, 18961-18965.	1.6	365
192	Cyclin A Links c-Myc to Adhesion-independent Cell Proliferation. <i>Journal of Biological Chemistry</i> , 1995, 270, 15923-15925.	1.6	42
193	Myc Target Genes in Cell Proliferation and Programmed Cell Death. <i>Medical Intelligence Unit</i> , 1995, , 171-192.	0.2	0
194	Max Association with Myc. <i>Medical Intelligence Unit</i> , 1995, , 151-163.	0.2	0
195	Properties of the c-Myc Protein. <i>Medical Intelligence Unit</i> , 1995, , 109-118.	0.2	0
196	Localization of the Human Mxi1 Transcription Factor Gene (MXI1) to Chromosome 10q24-q25. <i>Genomics</i> , 1994, 21, 669-672.	1.3	32
197	Function of the c-Myc oncoprotein. <i>FASEB Journal</i> , 1992, 6, 3065-3072.	0.2	155
198	c-Myc oncoprotein function. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1991, 1072, 103-113.	3.3	32

#	ARTICLE	IF	CITATIONS
199	Involvement of the 'leucine zipper' region in the oligomerization and transforming activity of human c-myc protein. <i>Nature</i> , 1989, 337, 664-666.	13.7	214
200	The Normal and Morbid Biology of Fibrinogen. <i>American Journal of Medicine</i> , 1989, 87, 567-576.	0.6	57
201	Detection and use of recombinant staphylococcal protein A fusion proteins to localize nucleic-acid-binding domains of proteins. <i>Analytical Biochemistry</i> , 1988, 174, 313-317.	1.1	4
202	Heparin requirement for the quantitation of fibrinogen production by primary hepatocyte cultures. <i>Analytical Biochemistry</i> , 1988, 170, 456-462.	1.1	2
203	Histidyl-tRNA synthetase, the myositis Jo-1 antigen, is cytoplasmic and unassociated with the cytoskeletal framework. <i>Experimental Cell Research</i> , 1986, 164, 261-266.	1.2	14
204	Application of a nitrocellulose immunoassay for quantitation of proteins secreted in culture media. <i>Analytical Biochemistry</i> , 1986, 158, 262-267.	1.1	15
205	Interactions of aminoacyl-tRNA synthetases in high-molecular-weight multienzyme complexes from rat liver. <i>BBA - Proteins and Proteomics</i> , 1985, 829, 319-326.	2.1	20
206	Intranuclear location of the myositis-specific Jo-1 antigen: Hopping histidyl-tRNA synthetase?. <i>Arthritis and Rheumatism</i> , 1985, 28, 839-840.	6.7	1
207	A case of agnogenic myeloid metaplasia evolving into acute myelogenous leukemia associated with the development of trisomy 11 in bone marrow cells. <i>American Journal of Hematology</i> , 1985, 19, 285-288.	2.0	7
208	Protective effect of divalent cations in the plasmin degradation of fibrinogen. <i>Archives of Biochemistry and Biophysics</i> , 1985, 238, 452-457.	1.4	11
209	Rat liver histidyl-tRNA synthetase. Purification and inhibition by the myositis-specific anti-Jo-1 autoantibody. <i>Biochemical and Biophysical Research Communications</i> , 1984, 120, 15-21.	1.0	36
210	Multienzyme complexes of eukaryotic aminoacyl-tRNA synthetases. <i>Bioscience Reports</i> , 1983, 3, 527-538.	1.1	27
211	Hydrodynamic properties and structure of the rat liver 12 S arginyl- and lysyl-tRNA synthetase complex. <i>Biochemical and Biophysical Research Communications</i> , 1983, 117, 464-469.	1.0	8
212	High molecular weight complex formation of rat liver lysyl-tRNA synthetase reduces enzyme lability to thermal inactivation. <i>Biochemical and Biophysical Research Communications</i> , 1982, 106, 44-47.	1.0	11
213	High molecular mass amino acyl-tRNA synthetase complexes in eukaryotes. <i>FEBS Letters</i> , 1982, 142, 1-6.	1.3	54
214	High molecular weight complexes of eukaryotic aminoacyl-trna synthetases. <i>International Journal of Biochemistry & Cell Biology</i> , 1982, 14, 539-543.	0.8	30
215	Tobacco-alcohol amblyopia: A proposed biochemical basis for pathogenesis. <i>Medical Hypotheses</i> , 1981, 7, 1317-1328.	0.8	25
216	ORGANIZATION OF MAMMALIAN AMINOACYL-tRNA SYNTHETASES. , 1978, , 575-580.		1